However, there is no clear evidence indicating that BRAF status impacts outcome in advanced melanoma treated with pembrolizumab, and patients with both BRAF wild‐type and BRAF mutant melanoma have been shown to benefit from treatment.23 This evidence concerns the gene BRAF and melanoma.